A phase Ib/II study of fruquintinib in combination with paclitaxel as the second‐line therapy for advanced gastric cancer

Detalles Bibliográficos
Autores principales: Zhang, Yang, Wang, Zi‐Xian, Shen, Lin, Li, Jin, Huang, Jing, Su, Wei‐Guo, Zhang, Dong‐Sheng, Xu, Rui‐Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859731/
https://www.ncbi.nlm.nih.gov/pubmed/36331272
http://dx.doi.org/10.1002/cac2.12379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859731/
https://www.ncbi.nlm.nih.gov/pubmed/36331272
http://dx.doi.org/10.1002/cac2.12379

Ejemplares similares